Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.
The RNA therapeutics market is rapidly growing but is currently limited by the scalability and sustainability issues inherent in decades-old solid phase synthesis technologies. Britton Jimenez, SVP of Sales and Marketing at Codexis, addresses these limitations and introduces the novel ECO Synthesis® Manufacturing Platform, a fully aqueous system that allows for massive batch sizes, feasibly scaling up to 500 kgs. He also details how Codexis utilizes machine learning and AI, building on its CodeEvolver platform history, to optimize manufacturing strategies and proactively engage with the FDA to ensure that customers have a clear regulatory pathway for bringing their therapeutics to market.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
